Genmab

This phase 3 study tests whether a new drug combination (epcoritamab plus lenalidomide) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 379 participants will receive either the new …

This phase 3 trial compares a new immunotherapy drug, epcoritamab, given as a shot under the skin, with standard chemotherapy for people with diffuse large B-cell lymphoma that has returned or stopped responding to at least one prior treatment. About 484 participants will be rand…

This study tests an experimental drug called epcoritamab, given alone or with other medicines, in about 195 people whose chronic lymphocytic leukemia (CLL) or Richter's syndrome has stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink o…

This phase 3 trial tests whether a new drug combination (acasunlimab plus pembrolizumab) helps people with a certain type of advanced lung cancer live longer compared to standard chemotherapy (docetaxel). The study includes about 191 adults whose cancer has gotten worse after pri…

This trial tests a new antibody drug called acasunlimab (GEN1046) in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, to find safe doses, and second, to see how well the drug works alone or combined with other …

This study tests an experimental drug called epcoritamab (GEN3013) in people with several types of B-cell lymphoma that have relapsed (come back) or are refractory (did not respond to prior treatment). The main goals are to find the safest and most effective dose, monitor side ef…

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 adults in China who cannot have a stem cell transplant will …

This study tests a drug called epcoritamab, given alone or with another drug (lenalidomide), in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy. The goal is to see if the treatment can shrink or eliminate the cancer. About 111 participant…

This study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal is …

This trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, for people with advanced non-small cell lung cancer that has returned or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously e…

This study tests an experimental drug called epcoritamab in Japanese adults whose B-cell lymphoma has come back or not responded to treatment. The trial has two parts: first, finding a safe dose, and second, checking how well the drug works alone or with other treatments. About 7…

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …

This study tests a new drug called acasunlimab, given alone or with pembrolizumab, in adults with advanced melanoma that got worse after standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer. Participants receive active treatment and are monitore…

This early-stage study tests a new drug called GEN1042, alone or with other cancer treatments, in Japanese adults with solid tumors. The main goal is to check safety and find the right dose. About 42 participants will be enrolled.